Venus Remedies Share Price

Incorporated in 1989 Venus Remedies Limited, formerly known as Venus Glucose Pvt Ltd, was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited. The Company was promoted and managed by Chaudhary Family. The Company is one of the handful player in pharmaceutical sector to launch injectables globally. It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). At present, Venus focuses on specialized therapeutic areas including antiinfectives (antibiotics), oncology, neurology, pain management, and skin and wound care. In priority, the Company was mainly engaged in I/V Fluids Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc.The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana. In 1994 it introduced Eye/Ear/Nose drops. The company received the certificate as WHOGMP as specified by WHO,Geneva. Venus Remedies set up a Cephalosporin project with an Australian collaboration with USFDA standards at a cost of Rs.4.5 crores. In 2001 with the help of Product Development Committee(PDC) Venus Remedies had introduced 13 new products in the Animal Health Division namely Megox3000,Paroxin3000,Pisa3000,Mical,Ronid,Dexolyte and Detox.The year 200506 saw many new milestone achievements by the Company like commercial operation of its most modern and technosavvy manufacturing unit at Baddi, formation of a WOS in Germany and acquisition of a running, GermanGMP certified pharmaceutical unit at Werne, Germany, launch of its second RD Product after DCGI Approval etc. There was a rigorous activity for development on all fronts and the Company made huge investments in projects at Panchkula, Baddi and now at Werne, Germany for renovations, new Projects and acquisition as well. The Company was the first to launch Injection Meropenem in Paediatric Dosage of 125 mg in its Domestic Marketing during the year 200607. It further launched fourth research product, a fixed dose combination of cephalosporin with aminoglycoside under the Tobracef brand in 200809. It launched its anticancer drug Docetaxel in Europe by end 2011, launched ACHNIL, the onceaday pain management therapy in India in 2011 launched Cytomib, a firsttime therapy against blood cancer in 2011 launched Taxedol in threestrengths20 mg, 80 mg and 120 mg in 2012.In 2013, the Company established preclinical proof of concept for its Drug ProteinPolymer Conjugate (DPPC) introduced ReadytoUse a Single Vial Taxedol in India launched Trois, a miracle nanoemulsion for arthritic Pain launched Elores CSE 1034, a US patent protected product in India, launched its first OTC product Ezenus. In 2014, the Company launched ELORES, an antibiotic to fight superbugs. In 202122, it launched first product in the consumer healthcare space, R3SET a Pain Management solution. Besides this, Venpocare dealing with Wound Healing was also launched during year 2022. To make internal processes smart and streamlined, many solutions including an automated order processing system, retail billing system, new warehouse (VFC) with barcode automation, etc. were launched. For quicker and more effective decisionmaking, a BI tool like Tableau was also launched in 2022.The Company has further launched new highvalue molecules, including Bendamustine, Azacitidine, Fulvestrant, Plerixafor, andSugammadex in FY 25.

For the full year FY2025–2026, revenue reached ₹668.84 crore and profit touched at ₹45.31 crore.

As of 11 Mar 2026, Venus Remedies share price is ₹861.7. The stock opened at ₹783.4 and had closed at ₹783.4 the previous day. During today’s trading session, Venus Remedies share price moved between ₹779.05 and ₹861.70, with an average price for the day of ₹820.38. Over the last 52 weeks, the stock has recorded a low of ₹277.95 and a high of ₹861.70. In terms of performance, Venus Remedies share price has increased by 89.8% over the past six months and has increased by 153.50% over the last year.